FEDERAL STREET STRATEGIES, LLC

Lobbying for BIOGEN, INC. · Biotechnology Company.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Jan 20, 2026

Lobbying activity 2

Health Issues

Issues related to Alzheimer's Disease and treatment. Amyotrophic lateral sclerosis (ALS), Lou Gehrigs Disease and treatment. Issues related to the FY2026 budget and appropriations process

Medicare/Medicaid

Issues related to rare diseases and treatment. Issues related to Mental Health treatment. Issues related to maternal health. Issues related to the FY2026 budget and appropriations process

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.